PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.
PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.
The user is seeking a knowledgeable trichologist or dermatologist in Belgium for a thorough scalp examination due to diffuse thinning and a previous diagnosis of male pattern baldness. They are interested in procedures like a trichogram and scalp biopsy.
Pyrilutamide did not show effectiveness in regrowing hair compared to a placebo, but it may still help maintain existing hair by preventing DHT from causing follicle miniaturization. Some users believe it could be beneficial when used with other treatments like minoxidil, finasteride, and dutasteride.
The user is experiencing diffuse androgenic alopecia and is trying various treatments, including 5mg finasteride, loniten, and Formula 82D, which contains dutasteride, a steroid, and tretinoin. They report potential regrowth with Formula 82D, despite previous treatments being ineffective.
A combination of pyrilutamide, minoxidil, and alfatradiol is proposed as an effective alternative to finasteride for treating mild to moderate hair loss, claiming to stabilize hair loss and improve thickness without finasteride's side effects. Some users are skeptical about the effectiveness and approval of these treatments, while others are interested in trying them due to finasteride's side effects.
The conversation is about finding a trustworthy and affordable source for RU58841 in Europe, with a comparison between Anagenic and Actifolic. The user seeks experiences from others in the EU to avoid receiving water instead of the product.
Taking finasteride 3 times a week can provide similar benefits to daily use with potentially fewer side effects. Some users switch to topical treatments or adjust dosages to manage side effects while maintaining hair health.
A 25-year-old male has been using finasteride since October 2022 to combat diffuse thinning and hairline recession, experiencing initial shedding but later stabilization. He plans to add oral minoxidil to improve hair density and is open to trying dutasteride if necessary, with minimal side effects reported.
The conversation discusses using Pyrilutamide, Alfatradiol 0.1%, and Minoxidil for hair loss treatment. Pyrilutamide is described as a strong antiandrogen, and Alfatradiol is noted for its effectiveness in inhibiting DHT on the scalp.
The conversation is about comparing the effectiveness of fluridil and clascoterone in preventing hair loss and inquiring about their use as standalone treatments. There is a question about the concentration of the fluridil brand for efficacy.
A user (seblt) who has had side effects from finasteride, minoxidil and RU58841 but is now trying pyrilutamide as a last resort, with other users providing advice and support. They have already seen some baby hairs growing after 10-14 days of treatment and will provide updates in 1-2 weeks.
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
The conversation humorously discusses hair loss treatments, focusing on the use of finasteride and dutasteride, with some users debating the effectiveness and cost of different dosages. Some users mention using topical minoxidil and express concerns about side effects and availability of higher doses.
The conversation is a humorous and hopeful prayer for the effectiveness of finasteride in combating hair loss. Participants express gratitude and support for the treatment.
A clinical trial for Verteporfin as a hair loss treatment, and the potential for greater progress in treatments for hair loss in the future. Common treatments such as Minoxidil, Finasteride and RU58841 were discussed.
Fluridil, a non-steroidal anti-androgen approved for alopecia in parts of Europe, is noted for its low side effects but is not commonly discussed. The user is inquiring if anyone prefers it over other anti-androgens like Spiro or RU58841.
Automatic-Law-3612's progress with hair loss treatments, including topical finasteride, topical dutasteride, minoxidil and pyrilutamide. They have been using these products for two weeks and noticed baby hairs in their temples getting longer.
The user experienced a sudden decrease in hair density after starting alfatradiol while already using finasteride. Another user mentioned that initial shedding can occur with hair loss treatments, but it may not last long.
Pyrilutamide powder is now available at a local supermarket in the Netherlands. The discussion humorously touches on hair loss treatments like Minoxidil, finasteride, and RU58841.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. A user asks about alfatradiol's availability, public perception, and usage in Germany.
Hair loss treatments, including Alfatradiol, Minoxidil, Finasteride, and RU58841. It discusses the efficacy of these treatments for hair growth and regrowth.
A user's experience of using Fin, Min and Microneedle treatments to help thicken their hair before undergoing a Hair Transplant (HT) procedure. The conversation also includes discussion about the results post-HT, including pictures.
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
Hair loss treatments discussed include alfatradiol, big 3, finasteride, RU58841, and stemoxydine. Alfatradiol is less effective but has fewer side effects, and mixing with stemoxydine may improve results.
Probiotics like L. reuteri ATCC PTA 6475 and B. longum BB536 may improve hair growth and density by reducing inflammation and reversing DHT damage. The user is trialing these probiotics personally, ordering them from the U.S. to Canada, and plans to continue if no adverse effects occur.
Alfatradiol is used as a mild treatment to slow or stabilize hair loss, often alongside finasteride and pumpkin seed oil. Users report reduced shedding and minimal side effects, but minoxidil is noted as more effective for regrowth.